Avanos Medical is currently navigating a challenging transition characterized by significant asset downsizing and inconsistent profitability, as evidenced by a $774.8 million accumulated deficit. While the company maintains a conservative debt-to-equity ratio ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 5, 2026 | $0.22+37.5% vs $0.16 | $182M+7.2% vs $170M |
Q1 2026 Feb 24, 2026 | $0.29+20.8% vs $0.24 | $181M+3.5% vs $175M |
Q4 2025 Nov 5, 2025 | $0.22+83.3% vs $0.12 | $178M+8.1% vs $165M |
Q3 2025 Aug 5, 2025 | $0.17-5.6% vs $0.18 | $175M+4.5% vs $168M |
Bank of America Corp DE grew its position in shares of Avanos Medical, Inc. (NYSE: AVNS) by 30.2% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 110,978 shares of the company's stock after purchasing an additional 25,767 shares during the quarter.
BlackRock Inc. purchased a new position in Avanos Medical, Inc. (NYSE: AVNS) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 7,468,794 shares of the company's stock, valued at approximately $185,824,000. BlackRock Inc. owned 15.94% of Avanos Medical at the end of
NEW YORK--(BUSINESS WIRE)--Sterlington advises Avanos Medical management team on $1.27 billion acquisition.
ALPHARETTA, Ga., July 22, 2026 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) ("Avanos" or the "Company"), a leading medical technology company, today announced that its stockholders have voted to approve the pending acquisition of Avanos by affiliates of investment funds advised by American Industrial Partners ("AIP") at a special meeting of stockholders (the "Special Meeting") held earlier today.
Benchmark AVNS against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Avanos Medical, Inc. (AVNS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $24.99 | $1.17B | -17.12 | 1.95% | -9.68% | -8.45% | — | |
| $87.07 | $5.19B | 40.88 | 11.66% | 9.22% | 9.07% | — | |
| $16.25 | $1.88B | -13.32 | 8.28% | -21.25% | -44% | — | |
| $126.32 | $4.29B | 43.71 | 7.57% | 6.97% | 7.43% | — | |
| $59.96 | $3.05B | -249.81 | 14.88% | 1.85% | 2.14% | — | |
| $390.79 | $55.97B | -257.10 | 35.9% | -7.11% | -11.73% | — |
Avanos Medical, Inc. (AVNS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Avanos Medical, Inc. (AVNS) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
Jul 22, 2026·SEC
Jul 15, 2026·SEC
Get notified when AVNS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Avanos Medical, Inc. (AVNS) stock FAQ — growth, dividends, profitability & financials explained
Avanos Medical, Inc. (AVNS) reported $715.9M in revenue for fiscal year 2025. This represents a 57% decrease from $1.68B in 2012.
Avanos Medical, Inc. (AVNS) grew revenue by 1.9% over the past year. Growth has been modest.
Avanos Medical, Inc. (AVNS) reported a net loss of $69.4M for fiscal year 2025.
Avanos Medical, Inc. (AVNS) has a return on equity (ROE) of -8.5%. Negative ROE indicates the company is unprofitable.
Avanos Medical, Inc. (AVNS) generated $7.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
